Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04538417
Other study ID # IRB 106250
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 27, 2019
Est. completion date August 30, 2023

Study information

Verified date March 2024
Source University of Utah
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To assess changes in pain, physical function, and health-related quality of life in patients with post-amputation neuroma-associated residual limb pain after cooled radiofrequency ablation.


Description:

Residual limb (RLP) and phantom limb pain (PLP) affects most amputees at some point in their life1. The incidence of PLP has been estimated to range between 50 - 80%. RLP prevalence has been estimated to be 43%. The peak of onset is bimodal and often appears within the first month and second year after amputation. RLP is more common in the first year after amputation, with PLP becoming the predominate amputee pain complaint after one-year post-amputation. Both RLP and PLP fall under the umbrella term "post-amputation pain." While these conditions are frequently found in combination, their clinical features and underlying causes are distinct. PLP is a painful sensation in the distribution of the missing limb. Following amputation, abnormalities at multiple levels of the neural axis have been implicated in the development of PLP; changes include cortical reorganization, reduced inhibitory processes at the spinal cord, synaptic response changes and hyperexcitability at the dorsal root ganglion, and retrograde peripheral nerves shrinkage. Residual limb pain has been called "neuroma pain" and is mechanistically distinct from PLP11. Neuromas may form as early 6-10 weeks after nerve transection, and are thought the produce ectopic neural discharges resulting in severe pain. Evidence suggests RLP and PLP commonly co-occur and patients may struggle to differentiate between these pain types. Risk factors include female sex, upper extremity amputation, pre-amputation pain, residual pain in contralateral limb, and time since amputation. Depression, anxiety, and stress are known to exacerbate PLP / RLP. Patients experiencing PLP and RLP also experience a higher incidence of indecisiveness, suicidal ideation, and thoughts of self-harm8. Current guidelines for treatment of PLP and RLP are not standardized. Treatments includes pre-operative analgesia, neuromodulation mirror therapy, imagery, acupuncture, transcranial stimulation, deep brain stimulation, and medications (including, but not limited to: TCAs, SSRIs, gabapentinoids, sodium channel blockers, ketamine, opioids, and NSAIDs). Many agents have been injected in neuromas. These include local anesthetic, phenol, alcohol, and botulinum toxin. These oral, intravenous, and nonpharmacological modalities have demonstrated limited success in the treatment of PLP / RLP. Neuroma cryoablation has been used, but this method of neural destruction poses technical challenges related to cumbersome needle placement and the requirement for time-intensive freeze-thaw cycles. Conventional RFA has been studied on RLP. Zhang et. al treated 13 patients with painful stump neuromas. The study started with alcohol neurolysis before using ultrasound-guided RFA for refractory cases. The frequency of sharp pain was reduced in all RFA-treated patients. Kim et. al described a case in which ultrasound-guided RFA was successfully used to treat a sciatic neuroma of an above-knee amputee. No outcome literature on the effectiveness of C-RFA technology has been published. C-RFA is similar in mechanism to conventional RFA: a thermal lesion is created by applying radiofrequency energy through an electrode placed at a target structure. In C-RFA, a constant flow of ambient water is circulated through the electrode via a peristaltic pump, maintaining a lowered tissue temperature by creating a heat sink. By removing heat from tissues immediately adjacent to the electrode tip, a lower lesioning temperature is maintained, resulting in less tissue charring adjacent to the electrode, less tissue impedance and more efficient heating of target tissue. The volume of tissue heated, and the resultant thermal lesion size is substantially larger with C-RFA, conferring an advantage over conventional RFA. Further, given the spherical geometry and forward projection the C-RFA lesions beyond the distal end of the electrode, the RFA probe can be positioned at a range of possible angles and still capture the target neural structure, whereas more fastidious, parallel positioning is required with conventional RFA. These technical advantages increase the probability of successful denervation of neural pain generators that have variability in anatomic location. Additionally, a longer lesion of the RLP-generating nerve may be more reliably achieved with C-RFA compared to conventional RFA. As such, the present study aims to define the attributable effect of cooled RFA on pain, physical function, and health-related quality of life in patients with post-amputation neuroma-associated residual limb pain. This prospective single-arm pilot study is intended to inform a future properly powered randomized controlled trial.


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date August 30, 2023
Est. primary completion date August 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age greater than 18 years of age at day of enrollment. 2. Clinical diagnosis lower extremity amputation performed more than 1 year since study enrollment. 3. Residual pain described as burning pain and sensations of movement in the affected amputated limb32. 4. Pain duration of more than 6 months despite a trial of conservative therapy (medications, physical therapy) for 2 months. 5. Ultrasound and / or MRI imaging pathology consistent with clinical symptoms and signs. 6. Greater than 50% pain relief with a diagnostic neuroma block Exclusion Criteria: 1. Refusal or inability to participate, provide consent, or provide follow-up information for the 12-month duration of the study. 2. Contraindications to diagnostic block or treatment ablation (active infection, bleeding disorders, and pregnancy or breastfeeding, active immunosuppression, participation in another phantom or residual limb pain trial within the last 30 days 3. Non-neurogenic source of residual or phantom limb pain. 4. Active moderate to severe lumbar radiculopathy. 5. Any injection in the residual limb within the last 30 days. 6. Severe uncontrolled medical condition as determined by treating physician. 7. Severe psychological illness. 8. History of Inflammatory arthritis. 9. Malignancy within past 5 years except basal cell or squamous cell skin cancer. 10. Current opioid use exceeding50morphinemilligram equivalents per day. 11. A history of alcohol or drug abuse within past 5 years. 12. Use of any investigational drug within past 30 days. 13. Pending litigation involving participant's residual limb pain. 14. Incarceration

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Cooled Radiofrequency Ablation
RFA procedures will be performed with modification accounting for appropriate C-RFA technique. Participant will be positioned prone and skin prepped with chloroprep. Ultrasound probe will be placed on residual limb at a transverse angle in order to view the nerve and associated neuroma in long-axis. The probe will be advanced to the site of the stump neuroma. C-RFA electrode will be placed adjacent to neuroma. Needle will be connected via wire to a cooled radiofrequency generator. Motor and sensory testing will be performed to reproduce or exacerbate the RLP and / or PLP. At the site of the neuroma, 2 mL of local anesthetic will be injected through the needle. C-RFA lesions will be created by using the typical C-RFA protocol. Upon completion needle will be removed. Following ablation, 0.5 mL of 0.5% bupivacaine will be injected at the site of the ablated neuroma to provide post procedure analgesia.

Locations

Country Name City State
United States University of Utah Salt Lake City Utah

Sponsors (1)

Lead Sponsor Collaborator
University of Utah

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Numeric Rating Scale (NRS) for Pain at 6 Months Presented here is the proportion of participants reporting =50% improvement in Numeric Rating Scale pain score at 6 months after their cooled radiofrequency ablation procedure. The Numeric Rating Scale was used to quantify neuroma-associated residual limb pain by asking patients to rate their pain intensity on an 11-point scale ranging from 0 to 10, with 0 representing "no pain at all" and 10 representing "the worst pain imaginable". 6 months
Secondary Median Change in Numeric Rating Scale (NRS) Scores for Pain Patients rated their residual limb pain intensity at baseline and the designated follow-up timepoints using an 11-point Numeric Rating Scale (NRS) ranging from 0 to 10, with 0 representing "no pain at all" and 10 representing "the worst pain imaginable". Change scores were calculated by subtracting follow-up scores from baseline scores. Median change scores and their interquartile ranges are reported here. Positive median change scores indicate pain improvement from baseline, with greater values corresponding to greater pain relief. Similarly, negative change scores indicate worsening pain from baseline. 1, 3, 6, and 12 months
Secondary Medication Quantification Scale III Mean Score Mean change in Medication Quantification Scale III (MQS III) score. All medications will be entered into the MQS III equation, which is used to determine the standardized cumulative detriment related to a particular medication regimen 4 years
Secondary Proportion of Patients With a =6 Score on Patient Global Impression of Change (PGIC) Patient Global Impression of Change is a scale which measures participant reported satisfaction after an intervention. The outcome was measured as the percent of patients reporting a PGIC score of 6-7 (indicating "much improved" and "very much improved"). 1, 3, 6, and 12 months
See also
  Status Clinical Trial Phase
Completed NCT04060875 - Research Protocol for Karuna Labs Inc.: Safety and Efficacy of Virtual Reality Graded Motor Imagery for Chronic Pain
Active, not recruiting NCT02519907 - Surface Electrical Stimulation for Treatment of Phantom Limb Pain N/A
Completed NCT02281539 - Myoelectrically Controlled Augmented Reality and Gaming for the Treatment of Phantom Limb Pain N/A
Completed NCT01608035 - Sciatic Perineural Versus Stump Catheter for Below Knee Amputation Phase 0
Completed NCT03111277 - MR Guided Focused Ultrasound for Treatment of Neuropathic Pain N/A
Recruiting NCT05188183 - Pragmatic Trial of Remote tDCS and Somatosensory Training for Phantom Limb Pain With Machine Learning to Predict Treatment Response N/A
Active, not recruiting NCT02221934 - Electrical Nerve Block for Amputation Pain N/A
Active, not recruiting NCT03029884 - Closed-loop Deep Brain Stimulation to Treat Refractory Neuropathic Pain N/A
Completed NCT03317600 - Postamputation Pain: Peripheral Mechanisms N/A
Completed NCT01996254 - Electrical Stimulation for the Treatment of Post-Amputation Pain Using the SPRINT System N/A
Terminated NCT00771862 - Prevention of Phantom Limb and Stump Pain Using Ambulatory Continuous Peripheral Nerve Blocks: A Pilot Study Phase 4
Completed NCT00462566 - The Efficacy of Motor Cortex Stimulation for Pain Control N/A
Completed NCT05684445 - The Effect of Distant Reiki on Pain and Holistic Well-being N/A
Completed NCT02784548 - Virtual Reality for Phantom Limb Pain N/A
Active, not recruiting NCT05915065 - VR to Evaluate Phantom Limb Pain N/A
Completed NCT00797849 - Controlled Study of Farabloc for Chronic Phantom Limb Pain Among Veteran Amputees N/A
Enrolling by invitation NCT05807607 - Study of Lower-limb Phantom Pain Syndrome Using Peripheral Nerve and Spinal Cord Stimulation N/A
Completed NCT03350061 - Prosthesis With Sensations N/A
Active, not recruiting NCT06428123 - Comparison of Efficacy of Mirror Therapy vs Mental Imagery in Reduction of Phantom Limb Pain in AKAP N/A
Enrolling by invitation NCT05650931 - Study of Phantom Limb Pain Using Peripheral Nerve and Spinal Cord Stimulation N/A